McGuire J J, Tsukamoto T, Hart B P, Coward J K, Kalman T I, Galivan J
Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
Invest New Drugs. 1996;14(3):317-23. doi: 10.1007/BF00194535.
Synthesis of poly(gamma-glutamate) metabolites of natural folates and antifolates is a critical process. Folypolyglutamates are essential for cell proliferation. Polyglutamates of glutamate (Glu)-containing antifolates are often critical for their cytotoxic action and are relevant to antifolate resistance. However, the role of polyglutamate synthesis in selectivity is less clear. We have undertaken a research program to further define the significance of polyglutamate metabolism and to devise ways to exploit this metabolism to achieve greater therapeutic selectivity in cancer chemotherapy. This article briefly reviews several approaches tested thus far. Inhibition of folypolyglutamate synthesis should lead to cell death. Current ornithine (Orn)-containing folate-based inhibitors of the enzyme responsible for their synthesis, folypolyglutamate synthetase (FPGS), are poorly transported, apparently because of interference by the protonated delta-amine. Replacement of Orn with 4, 4-difluoroOrn, the delta-amine of which has a much lower pKa and is thus less protonated at physiological pH, was explored. Since it is unclear how polyglutamylation contributes to selectivity, we explored generic means either to eliminate or to enhance polyglutamylation. The data indicate that substitution for Glu in an antifolate by some Glu analogs in which the gamma-COOH is either altered or replaced (e.g., gamma-tetrazole-Glu) leads to loss of both FPGS substrate activity and binding; antifolate target specificity is unchanged, while uptake is actually enhanced. Substitution of 3,3-difluoroGlu for Glu leads to enhanced polyglutamylation (although probably only to the diglutamate), retention of target specificity, and at least equal uptake. Comparative studies of the same antifolate containing different replacements for Glu, such as gamma-tetrazole-Glu (no polyglutamylation) or 3,3-difluoroGlu (enhanced polyglutamylation), will be useful in exploring the role and significance of polyglutamylation.
天然叶酸和抗叶酸剂的聚(γ-谷氨酸)代谢物的合成是一个关键过程。叶酸多聚谷氨酸对于细胞增殖至关重要。含谷氨酸(Glu)的抗叶酸剂的多聚谷氨酸通常对其细胞毒性作用至关重要,并且与抗叶酸耐药性相关。然而,多聚谷氨酸合成在选择性方面的作用尚不清楚。我们开展了一项研究计划,以进一步明确多聚谷氨酸代谢的意义,并设计方法利用这种代谢在癌症化疗中实现更高的治疗选择性。本文简要综述了迄今为止测试的几种方法。抑制叶酸多聚谷氨酸合成应导致细胞死亡。目前基于鸟氨酸(Orn)的叶酸类抑制剂可抑制负责其合成的酶——叶酸多聚谷氨酸合成酶(FPGS),但其转运性较差,显然是由于质子化的δ-胺的干扰。人们探索了用4,4-二氟鸟氨酸替代Orn,其δ-胺的pKa低得多,因此在生理pH下质子化程度较低。由于尚不清楚多聚谷氨酰化如何影响选择性,我们探索了消除或增强多聚谷氨酰化的通用方法。数据表明,用一些γ-羧基被改变或取代的Glu类似物(例如γ-四唑-Glu)替代抗叶酸剂中的Glu会导致FPGS底物活性和结合能力丧失;抗叶酸剂的靶点特异性不变,而摄取实际上增强。用3,3-二氟Glu替代Glu会导致多聚谷氨酰化增强(尽管可能仅到二谷氨酸)、靶点特异性保留以及至少相同的摄取。对含有不同Glu替代物的相同抗叶酸剂进行比较研究,例如γ-四唑-Glu(无多聚谷氨酰化)或3,3-二氟Glu(多聚谷氨酰化增强),将有助于探索多聚谷氨酰化的作用和意义。